G1 Therapeutics (GTHX) Scheduled to Post Quarterly Earnings on Wednesday

G1 Therapeutics (NASDAQ:GTHX) will announce its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative net margin of 58.13% and a negative return on equity of 106.04%. The company had revenue of $14.87 million for the quarter, compared to analysts’ expectations of $12.83 million. During the same quarter in the previous year, the company posted ($0.73) EPS. On average, analysts expect G1 Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

G1 Therapeutics Stock Up 3.4 %

GTHX stock opened at $3.99 on Monday. The firm has a market cap of $208.40 million, a PE ratio of -4.20 and a beta of 1.73. G1 Therapeutics has a 12 month low of $1.08 and a 12 month high of $5.00. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.87 and a quick ratio of 3.45. The firm has a 50 day simple moving average of $3.75 and a 200 day simple moving average of $3.00.

Analyst Ratings Changes

GTHX has been the topic of several research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price target on shares of G1 Therapeutics in a report on Friday, April 12th. Wedbush reaffirmed an “outperform” rating and set a $5.00 target price (up from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th.

Insider Activity at G1 Therapeutics

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the transaction, the insider now directly owns 169,938 shares in the company, valued at approximately $785,113.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.23% of the stock is owned by insiders.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.